These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nitric oxide inhibits viral replication in murine myocarditis. Lowenstein CJ; Hill SL; Lafond-Walker A; Wu J; Allen G; Landavere M; Rose NR; Herskowitz A J Clin Invest; 1996 Apr; 97(8):1837-43. PubMed ID: 8621766 [TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. Yun SH; Lee WG; Kim YC; Ju ES; Lim BK; Choi JO; Kim DK; Jeon ES J Infect Dis; 2012 Feb; 205(3):491-7. PubMed ID: 22207647 [TBL] [Abstract][Full Text] [Related]
6. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Mikami S; Kawashima S; Kanazawa K; Hirata K; Katayama Y; Hotta H; Hayashi Y; Ito H; Yokoyama M Biochem Biophys Res Commun; 1996 Mar; 220(3):983-9. PubMed ID: 8607880 [TBL] [Abstract][Full Text] [Related]
7. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Zell R; Markgraf R; Schmidtke M; Görlach M; Stelzner A; Henke A; Sigusch HH; Glück B Med Microbiol Immunol; 2004 May; 193(2-3):91-100. PubMed ID: 14513374 [TBL] [Abstract][Full Text] [Related]
8. Nitric oxide and Coxsackievirus B3 myocarditis: differential expression of inducible nitric oxide synthase in mouse heart after infection with virulent or attenuated virus. Bevan AL; Zhang H; Li Y; Archard LC J Med Virol; 2001 Jun; 64(2):175-82. PubMed ID: 11360250 [TBL] [Abstract][Full Text] [Related]
9. The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Zaragoza C; Ocampo C; Saura M; Leppo M; Wei XQ; Quick R; Moncada S; Liew FY; Lowenstein CJ Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2469-74. PubMed ID: 9482909 [TBL] [Abstract][Full Text] [Related]
10. Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice. Jiang Y; Zhu Y; Mu Q; Luo H; Zhi Y; Shen X Antiviral Res; 2017 May; 141():133-139. PubMed ID: 28115196 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Suda O; Tsutsui M; Morishita T; Tanimoto A; Horiuchi M; Tasaki H; Huang PL; Sasaguri Y; Yanagihara N; Nakashima Y Circulation; 2002 Sep; 106(13):1729-35. PubMed ID: 12270870 [TBL] [Abstract][Full Text] [Related]
13. Myocardial vasoactive intestinal peptide and fibrosis induced by nitric oxide synthase inhibition in the rat. Ye VZ; Hodge G; Yong JL; Duggan KA Acta Physiol Scand; 2003 Dec; 179(4):353-60. PubMed ID: 14656372 [TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. Yue-Chun L; Teng Z; Na-Dan Z; Li-Sha G; Qin L; Xue-Qiang G; Jia-Feng L PLoS One; 2012; 7(6):e39394. PubMed ID: 22761780 [TBL] [Abstract][Full Text] [Related]
15. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse. Kishimoto C; Takada H; Hiraoka Y; Shiraki K Cardiovasc Res; 1995 Jan; 29(1):80-4. PubMed ID: 7895243 [TBL] [Abstract][Full Text] [Related]
16. Intracellular viral localization in murine coxsackievirus-B3 myocarditis. Ultrastructural study by electron microscopic in situ hybridization. Ukimura A; Deguchi H; Kitaura Y; Fujioka S; Hirasawa M; Kawamura K; Hirai K Am J Pathol; 1997 Jun; 150(6):2061-74. PubMed ID: 9176398 [TBL] [Abstract][Full Text] [Related]
17. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Hu L; Sealey JE; Chen R; Zhou Y; Merali C; Shi Y; Laragh JH; Catanzaro DF Am J Hypertens; 2004 May; 17(5 Pt 1):395-403. PubMed ID: 15110897 [TBL] [Abstract][Full Text] [Related]
18. Development of cardiomyocyte hypotrophy in rats under prolonged treatment with a low dose of a nitric oxide synthesis inhibitor. de Oliveira CF; Cintra KA; Teixeira SA; De Luca IM; Antunes E; De Nucci G Eur J Pharmacol; 2000 Mar; 391(1-2):121-6. PubMed ID: 10720643 [TBL] [Abstract][Full Text] [Related]